Arcitumomab

N/A

Report date: 2025/09/05 17:58:18

Base Information

Drug NameArcitumomab
Drug Alias Name阿西莫单抗ImmuRAID-CEA-Tc-99mTechnetium Tc 99m arcitumomab阿西妥莫单抗Tc-99m arcitumomab +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6] 
Mechanisms of ActionSingle-photon emission-computed tomography enhancersCarcinoembryonic antigen related cell adhesion molecule 5 antagonists
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1996/06/28
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesImmunomedics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunomedics GmbhImmunomedics Inc
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeV09IA06
Related LinksWikipediaDrugBankKEGG